share_log

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K：重大事件
美股SEC公告 ·  08/28 16:48
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. has filed a Form 8-K with the SEC on August 28, 2024, detailing its ongoing acquisition process of Exscientia plc. The acquisition, which was initially disclosed in a previous report on August 8, 2024, is subject to stockholder approval from both companies and will be executed through a Scheme of Arrangement under UK law. As part of the acquisition agreement, shareholders of Exscientia holding approximately 42% of its share capital have committed to vote in favor of the transaction through irrevocable undertakings. Additionally, Evotec SE, holding about 11% of Exscientia's share capital, has also entered into an irrevocable undertaking to support the acquisition. Collectively, these shareholders control approximately 53% of Exscientia's shares. The transaction is to be further detailed in a joint proxy statement to be filed with the SEC, which will outline the terms and benefits of the proposed acquisition. Recursion Pharmaceuticals advises investors and security holders to read the proxy statement and other relevant documents carefully once available, as they will contain important information about the transaction.
Recursion Pharmaceuticals, Inc. has filed a Form 8-K with the SEC on August 28, 2024, detailing its ongoing acquisition process of Exscientia plc. The acquisition, which was initially disclosed in a previous report on August 8, 2024, is subject to stockholder approval from both companies and will be executed through a Scheme of Arrangement under UK law. As part of the acquisition agreement, shareholders of Exscientia holding approximately 42% of its share capital have committed to vote in favor of the transaction through irrevocable undertakings. Additionally, Evotec SE, holding about 11% of Exscientia's share capital, has also entered into an irrevocable undertaking to support the acquisition. Collectively, these shareholders control approximately 53% of Exscientia's shares. The transaction is to be further detailed in a joint proxy statement to be filed with the SEC, which will outline the terms and benefits of the proposed acquisition. Recursion Pharmaceuticals advises investors and security holders to read the proxy statement and other relevant documents carefully once available, as they will contain important information about the transaction.
Recursion Pharmaceuticals, Inc.已于2024年8月28日向美国证券交易委员会提交了8-k表格，详细说明其对Exscientia plc的持续收购过程。这项收购最初在2024年8月8日的一份先前报告中披露，需经两家公司的股东批准，并将通过英国法律下的安排方案进行执行。作为收购协议的一部分，Exscientia的股东大约持有其42%的股本已做出不可撤销的承诺，同意投票支持该交易。此外，持有Exscientia约11%股本的Evotec SE也已签署了一份不可撤销的承诺，支持这项收购。这些股东共同控制着Exscientia约53%的股份。该交易将在与美国证券交易委员会提交的联合代理声明中进一步详细说明，该声明将概述拟议收购的条款和利益。Recursion Pharmaceuticals建议投资者和安全持有人一旦有相关文件可用就要仔细阅读代理声明和其他相关文件，因为这些文件将包含有关交易的重要信息。
Recursion Pharmaceuticals, Inc.已于2024年8月28日向美国证券交易委员会提交了8-k表格，详细说明其对Exscientia plc的持续收购过程。这项收购最初在2024年8月8日的一份先前报告中披露，需经两家公司的股东批准，并将通过英国法律下的安排方案进行执行。作为收购协议的一部分，Exscientia的股东大约持有其42%的股本已做出不可撤销的承诺，同意投票支持该交易。此外，持有Exscientia约11%股本的Evotec SE也已签署了一份不可撤销的承诺，支持这项收购。这些股东共同控制着Exscientia约53%的股份。该交易将在与美国证券交易委员会提交的联合代理声明中进一步详细说明，该声明将概述拟议收购的条款和利益。Recursion Pharmaceuticals建议投资者和安全持有人一旦有相关文件可用就要仔细阅读代理声明和其他相关文件，因为这些文件将包含有关交易的重要信息。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息